Antibody-mediated Rejection Prevention Market
Market Insights on Antibody-mediated Rejection Prevention covering sales outlook, demand forecast & up-to-date key trends
Antibody-mediated Rejection Prevention Market by Treatment, End User & Region | Forecast 2023 to 2033
Antibody-mediated Rejection Prevention Market Snapshot (2023 to 2033)
The global antibody-mediated rejection prevention market is expected to be valued at US$ 89 million in 2023 and is projected to rise at a CAGR of 16% from 2023 to 2033. A valuation of US$ 528.31 million has been estimated by the end of the said decade. During the last decade, the complement system has gained prominence as a significant component of the AMR market. The primary goal of using complement inhibitors is to prevent DSA-induced allograft damage. As a result, it is expected to spur market growth.
Emerging technologies, such as genomic research and donor-specific antibody detection and definition assays, have provided significant insights into the pathophysiology and prognosis of severe antibody-mediated rejection. As a result, this aspect contributed heavily to the antibody-mediated rejection prevention industry. Antibody-mediated rejection prevention is predicted to exhibit a substantial increase due to increasing pervasiveness and the anticipated unveiling of therapeutic strategies such as Clazakizumab, Imlifidase, VIB4920, Inebilizumab-cdon, Daratumumab, and others projected timeframe. The United States had the maximum AMR occurrence population, with around 3,266 cases in 2020.
According to Penn Medicine News, the shortage of kidneys remains a public health crisis in the United States. Every year, approximately 20,000 transplants are performed, and over 90,000 people are on the waiting list for kidney transplants. Furthermore, 5,000 people die while waiting for a transplant. As a result, rising late kidney transplant failure is expected to drive industry growth over the forecast period.
The rising incidence of chronic illnesses such as cancer, and heart disease, among others, is growing significantly for biologics, which is expected to drive the monoclonal antibodies segment. Correspondingly, expanding implementations of mAb treatments for therapeutic targets, as well as increased awareness of such treatment options among patients and doctors are predicted to contribute substantially to segment growth. On the other hand, Robust advancement and research against a variety of diseases, including multiple sclerosis, rheumatoid arthritis, Crohn's disorder, and many others, has led to the creation of new therapeutics, which are expected to aid in the Immunomodulators segment's expansion. Over the projected timeframe, the immunomodulators segment is predicted to expand at a CAGR of 6.3%.
North America is expected to dominate the market. This region's prominence is credited to the rising prevalence of illnesses among the US inhabitants. Another significant contribution to the region's growth is the existence of major players, combined with the introduction of innovative products. Europe ranks second in the market due to its investments in science and technology for the creation of efficient drugs. This, along with increased immunosuppressant sales revenue, is expected to propel the market growth during the forecast period. Furthermore, Asia Pacific is expected to experience the fastest CAGR due to the expanding number of clinical trial experiments pertaining to several drugs and the region's expanding geriatric population.
Data Points |
Key Statistics |
Expected Market Value (2023) |
US$ 89 million |
Anticipated Forecast Value (2033) |
US$ 528.31 million |
Projected Growth Rate (2023-2033) |
16% CAGR |
Let us know your requirement to get
100% FREE customization
2018-2022 Antibody-mediated Rejection Prevention Demand Analysis vs. Forecast 2023-2033
The COVID-19 pandemic hampered the production, dispersion, and manufacturing of pharmaceuticals worldwide. Furthermore, owing to social distancing, footfall in clinics and medical institutions has dropped by more than 70% throughout this pandemic, resulting in a reduction in the volume of surgical operations, clinical trials, activities for research and development, and other pursuits, all of which have hampered market growth in the historical period.
However, when the industries got back to their normal functioning some companies considerably enhanced their logistics operations, augmented their R&D capabilities, and are involved more in production management and quality assurance. According to a report from Future Market Insights (FMI). From 2018 to 2022, sales witnessed significant growth, registering a CAGR of 14%.
Which are Some Prominent Drivers of the Antibody-mediated Rejection Prevention Market?
An expanding geriatric population base to propel market expansion
The population with end-stage kidney impairment is getting older. Nearly half of all new patient populations are over the age of 65, and one-third are over the age of 70. As a result, late kidney transplant failure is prevalent in the elderly population, which is predicted to propel the antibody-mediated rejection prevention market throughout the forecast period.
According to a Pew Research Center report, the aged population in the United States will increase to 81 million by 2050, up from 37 million in 2005. As a consequence, this factor is anticipated to contribute to industry development.
A robust drug pipeline to aid in providing more development opportunities
Year after year, research and advancement with the goal of providing advanced patient care accelerates. Experimental studies with new or existing therapeutic agents are leading to combination treatment. It has resulted in an increase in pipeline aspirants for a variety of condition prevention strategies, including antibody-mediated rejection.
Plegridy and Daclizumab by Biogen, Ocrelizumab by Roche, and Receptors' RPC-1063 and Nerventra by Teva Pharmaceuticals, for example, are expected to be available on the market during the projected timeline. Such immunomodulators are expected to garner a significant market share in the coming years, resulting in industry growth.
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystWhat are the Challenges Projected to be Faced by the Market?
Difficulties in constructing clinical trials to restrict market growth
There are obstacles to the expansion of the antibody-mediated rejection prevention market, such as difficulties in constructing clinical trials, a significant clinical burden, and the requirement for evidence-based treatment protocols.
Region-Wise Insights
What Makes North America the Largest Market for Antibody-mediated Rejection Prevention?
Therapeutic approaches and Development of algorithms to detect AMR drive market growth
Few therapeutic interventions have received FDA approval in the United States. The first is belatacept, which was recently approved for the treatment of severe rejection in the United States. Belatacept impeded DSA in phase 3 trials, while there was more intense cellular refusal, renal function upgraded.
Besides that, DeKAF is an NIH-funded experimental research of late allograft failure that is being carried out at five transplant centers in the United States and two in Canada. DeKAF Genomics is a peripheral study of DeKAF that is connected to Medicare claims data for patients in the United States. As a result, this factor is expected to propel market expansion.
Furthermore, the region's dominance is due to the rising prevalence of diseases among the US population. Another significant contributing factor to the region's expansion is the existence of key players, combined with the emergence of new products.
Why is Europe Considered a Lucrative Region for the Antibody-mediated Rejection Prevention Market?
Increasing Medical Expenditure is Spurring Demand for Antibody-mediated Rejection Prevention
Europe ranks second in the market due to its investments in scientific and technological research for the creation of high-quality drugs. Furthermore, according to a National Institute for Health and Care Excellence article, there were 4,647 individuals on the UK kidney waitlist in March 2019, and 3,280 adult kidney-only transplants in the UK in 2018/19 (with 71% coming from deceased donors). As a result, this factor is anticipated to contribute to market growth.
Collaboration efforts by the largest pharmaceutical and clinical-stage development firms, on the other side, will provide fresh avenues for monoclonal antibody expansion, which is anticipated to contribute to market expansion.

A unified Market Research Subscription Platform, built for today's disparate research needs.
Category-Wise Insights
Which Treatment Type Leads the Market for Antibody-mediated Rejection Prevention?
Monoclonal Antibodies to Lead the Treatment Type of Antibody-mediated Rejection Prevention
The global monoclonal antibodies segment was worth US$ 186 million in 2021, and it is expected to expand at a compound annual growth rate (CAGR) of 11% between 2023 and 2033.
Because mAbs are a potential solution for COVID-19 remediation owing to their safety and efficiency, the U.S. FDA has granted several antibody emergency use authorizations (EUA). As a result, these factors are anticipated to propel the monoclonal antibodies segment during the forecast period.
By End User, which Segment is Projected to Lead the Market?
Hospital Segment is Estimated to Hold the Largest Share
The hospital segment is predicted to maintain a dominant position in the market throughout the forthcoming years due to a rise in hospitalization rates and hospital healthcare services. Furthermore, between 2023 and 2033, the same segment is expected to experience the fastest CAGR.
Market Competition
Key players in the Antibody-mediated Rejection Prevention market are CSL Behring, Hansa Biopharma, Sanofi, Talaris Therapeutics, Horizon Therapeutics, Novartis AG, Biogen, Teva Pharmaceutical Industries Ltd., Eli Lilly, and Company, Bristol-Myers & Squibb Company. Some of the recent developments are below:
- Horizon Therapeutics plc revealed in February 2021 that it will procure Viela Bio, Inc. to significantly expand its product portfolio and thrive its rare disease medical portfolio.
- The trial's Independent Data Monitoring Committee has recommended that the evaluation of Jardiance® (empagliflozin) in grownups with chronic kidney disease (CKD) be halted early. Following a formal interim evaluation that met prede?ned criteria for favorable efficacy, the Medical Research Council (MRC) Population Health Research Unit reported in March 2022.
Report Scope
Report Attribute |
Details |
Market Value in 2023 |
US$ 89 million |
Market Value in 2033 |
US$ 528.31 million |
Growth Rate |
CAGR of 16% from 2023 to 2033 |
Base Year for Estimation |
2022 |
Historical Data |
2018 to 2022 |
Forecast Period |
2023 to 2033 |
Quantitative Units |
Revenue in US$ Million and CAGR from 2023-2033 |
Report Coverage |
Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
Segments Covered |
|
Regions Covered |
|
Key Countries Profiled |
|
Key Companies Profiled |
|
Customization |
Available Upon Request |
Key Segments Profiled in the Antibody-mediated Rejection Prevention Market Survey
By Treatment:
- Monoclonal Antibodies
- Cysteine Protease Inhibitors
- Immunomodulators
- Plasmapheresis
By End User:
- Hospitals
- Specialty Clinics
By Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Frequently Asked Questions
What is the anticipated growth of the Antibody-mediated Rejection Prevention market until 2033?
FMI projects the global Antibody-mediated Rejection Prevention market to expand at a 16% value CAGR by 2033.
What is the estimated market value of the Antibody-mediated Rejection Prevention market expected in 2023?
The global Antibody-mediated Rejection Prevention market is estimated at a market value of US$ 89 Million.
What is the estimated market value of the Antibody-mediated Rejection Prevention market expected in 2033?
The global Antibody-mediated Rejection Prevention market is expected to garner a market value of US$ 528.31 Million.
Which region is forecast to be the most lucrative for Antibody-mediated Rejection Prevention market growth?
FMI has projected North America to be one of the key regions for the Antibody-mediated Rejection Prevention market.
Which are some prominent Antibody-mediated Rejection Prevention manufacturers?
CSL Behring, Hansa Biopharma, Sanofi, Talaris Therapeutics, Horizon Therapeutics, Novartis AG, Biogen, Teva Pharmaceutical Industries Ltd., Eli Lilly and Company, Bristol-Myers & Squibb Company.
Table of Content
1. Executive Summary 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. PESTLE and Porter’s Analysis 3.6. Regulatory Landscape 3.6.1. By Key Regions 3.6.2. By Key Countries 3.7. Regional Parent Market Outlook 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022 4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) Analysis By Treatment, 2018 to 2022 5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Treatment, 2023 to 2033 5.3.1. Monoclonal Antibodies 5.3.2. Cysteine Protease Inhibitors 5.3.3. Immunomodulators 5.3.4. Plasmapheresis 5.4. Y-o-Y Growth Trend Analysis By Treatment, 2018 to 2022 5.5. Absolute $ Opportunity Analysis By Treatment, 2023 to 2033 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) Analysis By End User, 2018 to 2022 6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End User, 2023 to 2033 6.3.1. Hospitals 6.3.2. Specialty Clinics 6.4. Y-o-Y Growth Trend Analysis By End User, 2018 to 2022 6.5. Absolute $ Opportunity Analysis By End User, 2023 to 2033 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 7.1. Introduction 7.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022 7.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033 7.3.1. North America 7.3.2. Latin America 7.3.3. Europe 7.3.4. Asia Pacific 7.3.5. MEA 7.4. Market Attractiveness Analysis By Region 8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 8.2.1. By Country 8.2.1.1. USA 8.2.1.2. Canada 8.2.2. By Treatment 8.2.3. By End User 8.3. Market Attractiveness Analysis 8.3.1. By Country 8.3.2. By Treatment 8.3.3. By End User 8.4. Key Takeaways 9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 9.2.1. By Country 9.2.1.1. Brazil 9.2.1.2. Mexico 9.2.1.3. Rest of Latin America 9.2.2. By Treatment 9.2.3. By End User 9.3. Market Attractiveness Analysis 9.3.1. By Country 9.3.2. By Treatment 9.3.3. By End User 9.4. Key Takeaways 10. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 10.2.1. By Country 10.2.1.1. Germany 10.2.1.2. United Kingdom 10.2.1.3. France 10.2.1.4. Spain 10.2.1.5. Italy 10.2.1.6. Rest of Europe 10.2.2. By Treatment 10.2.3. By End User 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Treatment 10.3.3. By End User 10.4. Key Takeaways 11. Asia Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 11.2.1. By Country 11.2.1.1. China 11.2.1.2. Japan 11.2.1.3. South Korea 11.2.1.4. Singapore 11.2.1.5. Thailand 11.2.1.6. Indonesia 11.2.1.7. Australia 11.2.1.8. New Zealand 11.2.1.9. Rest of Asia Pacific 11.2.2. By Treatment 11.2.3. By End User 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Treatment 11.3.3. By End User 11.4. Key Takeaways 12. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 12.2.1. By Country 12.2.1.1. GCC Countries 12.2.1.2. South Africa 12.2.1.3. Israel 12.2.1.4. Rest of MEA 12.2.2. By Treatment 12.2.3. By End User 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Treatment 12.3.3. By End User 12.4. Key Takeaways 13. Key Countries Market Analysis 13.1. USA 13.1.1. Pricing Analysis 13.1.2. Market Share Analysis, 2022 13.1.2.1. By Treatment 13.1.2.2. By End User 13.2. Canada 13.2.1. Pricing Analysis 13.2.2. Market Share Analysis, 2022 13.2.2.1. By Treatment 13.2.2.2. By End User 13.3. Brazil 13.3.1. Pricing Analysis 13.3.2. Market Share Analysis, 2022 13.3.2.1. By Treatment 13.3.2.2. By End User 13.4. Mexico 13.4.1. Pricing Analysis 13.4.2. Market Share Analysis, 2022 13.4.2.1. By Treatment 13.4.2.2. By End User 13.5. Germany 13.5.1. Pricing Analysis 13.5.2. Market Share Analysis, 2022 13.5.2.1. By Treatment 13.5.2.2. By End User 13.6. United Kingdom 13.6.1. Pricing Analysis 13.6.2. Market Share Analysis, 2022 13.6.2.1. By Treatment 13.6.2.2. By End User 13.7. France 13.7.1. Pricing Analysis 13.7.2. Market Share Analysis, 2022 13.7.2.1. By Treatment 13.7.2.2. By End User 13.8. Spain 13.8.1. Pricing Analysis 13.8.2. Market Share Analysis, 2022 13.8.2.1. By Treatment 13.8.2.2. By End User 13.9. Italy 13.9.1. Pricing Analysis 13.9.2. Market Share Analysis, 2022 13.9.2.1. By Treatment 13.9.2.2. By End User 13.10. China 13.10.1. Pricing Analysis 13.10.2. Market Share Analysis, 2022 13.10.2.1. By Treatment 13.10.2.2. By End User 13.11. Japan 13.11.1. Pricing Analysis 13.11.2. Market Share Analysis, 2022 13.11.2.1. By Treatment 13.11.2.2. By End User 13.12. South Korea 13.12.1. Pricing Analysis 13.12.2. Market Share Analysis, 2022 13.12.2.1. By Treatment 13.12.2.2. By End User 13.13. Singapore 13.13.1. Pricing Analysis 13.13.2. Market Share Analysis, 2022 13.13.2.1. By Treatment 13.13.2.2. By End User 13.14. Thailand 13.14.1. Pricing Analysis 13.14.2. Market Share Analysis, 2022 13.14.2.1. By Treatment 13.14.2.2. By End User 13.15. Indonesia 13.15.1. Pricing Analysis 13.15.2. Market Share Analysis, 2022 13.15.2.1. By Treatment 13.15.2.2. By End User 13.16. Australia 13.16.1. Pricing Analysis 13.16.2. Market Share Analysis, 2022 13.16.2.1. By Treatment 13.16.2.2. By End User 13.17. New Zealand 13.17.1. Pricing Analysis 13.17.2. Market Share Analysis, 2022 13.17.2.1. By Treatment 13.17.2.2. By End User 13.18. GCC Countries 13.18.1. Pricing Analysis 13.18.2. Market Share Analysis, 2022 13.18.2.1. By Treatment 13.18.2.2. By End User 13.19. South Africa 13.19.1. Pricing Analysis 13.19.2. Market Share Analysis, 2022 13.19.2.1. By Treatment 13.19.2.2. By End User 13.20. Israel 13.20.1. Pricing Analysis 13.20.2. Market Share Analysis, 2022 13.20.2.1. By Treatment 13.20.2.2. By End User 14. Market Structure Analysis 14.1. Competition Dashboard 14.2. Competition Benchmarking 14.3. Market Share Analysis of Top Players 14.3.1. By Regional 14.3.2. By Treatment 14.3.3. By End User 15. Competition Analysis 15.1. Competition Deep Dive 15.1.1. CSL Behring 15.1.1.1. Overview 15.1.1.2. Product Portfolio 15.1.1.3. Profitability by Market Segments 15.1.1.4. Sales Footprint 15.1.1.5. Strategy Overview 15.1.1.5.1. Marketing Strategy 15.1.2. Hansa Biopharma 15.1.2.1. Overview 15.1.2.2. Product Portfolio 15.1.2.3. Profitability by Market Segments 15.1.2.4. Sales Footprint 15.1.2.5. Strategy Overview 15.1.2.5.1. Marketing Strategy 15.1.3. Sanofi 15.1.3.1. Overview 15.1.3.2. Product Portfolio 15.1.3.3. Profitability by Market Segments 15.1.3.4. Sales Footprint 15.1.3.5. Strategy Overview 15.1.3.5.1. Marketing Strategy 15.1.4. Talaris Therapeutics 15.1.4.1. Overview 15.1.4.2. Product Portfolio 15.1.4.3. Profitability by Market Segments 15.1.4.4. Sales Footprint 15.1.4.5. Strategy Overview 15.1.4.5.1. Marketing Strategy 15.1.5. Horizon Therapeutics 15.1.5.1. Overview 15.1.5.2. Product Portfolio 15.1.5.3. Profitability by Market Segments 15.1.5.4. Sales Footprint 15.1.5.5. Strategy Overview 15.1.5.5.1. Marketing Strategy 15.1.6. Novartis AG 15.1.6.1. Overview 15.1.6.2. Product Portfolio 15.1.6.3. Profitability by Market Segments 15.1.6.4. Sales Footprint 15.1.6.5. Strategy Overview 15.1.6.5.1. Marketing Strategy 15.1.7. Biogen 15.1.7.1. Overview 15.1.7.2. Product Portfolio 15.1.7.3. Profitability by Market Segments 15.1.7.4. Sales Footprint 15.1.7.5. Strategy Overview 15.1.7.5.1. Marketing Strategy 15.1.8. Teva Pharmaceutical Industries Ltd. 15.1.8.1. Overview 15.1.8.2. Product Portfolio 15.1.8.3. Profitability by Market Segments 15.1.8.4. Sales Footprint 15.1.8.5. Strategy Overview 15.1.8.5.1. Marketing Strategy 15.1.9. Eli Lilly and Company 15.1.9.1. Overview 15.1.9.2. Product Portfolio 15.1.9.3. Profitability by Market Segments 15.1.9.4. Sales Footprint 15.1.9.5. Strategy Overview 15.1.9.5.1. Marketing Strategy 15.1.10. Bristol-Myers & Squibb Company 15.1.10.1. Overview 15.1.10.2. Product Portfolio 15.1.10.3. Profitability by Market Segments 15.1.10.4. Sales Footprint 15.1.10.5. Strategy Overview 15.1.10.5.1. Marketing Strategy 16. Assumptions & Acronyms Used 17. Research Methodology
Let us know your requirement to get
100% FREE customization
List of Tables
Table 1: Global Market Value (US$ Million) Forecast by Region, 2018 to 2033 Table 2: Global Market Value (US$ Million) Forecast by Treatment, 2018 to 2033 Table 3: Global Market Value (US$ Million) Forecast by End User, 2018 to 2033 Table 4: North America Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 5: North America Market Value (US$ Million) Forecast by Treatment, 2018 to 2033 Table 6: North America Market Value (US$ Million) Forecast by End User, 2018 to 2033 Table 7: Latin America Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 8: Latin America Market Value (US$ Million) Forecast by Treatment, 2018 to 2033 Table 9: Latin America Market Value (US$ Million) Forecast by End User, 2018 to 2033 Table 10: Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 11: Europe Market Value (US$ Million) Forecast by Treatment, 2018 to 2033 Table 12: Europe Market Value (US$ Million) Forecast by End User, 2018 to 2033 Table 13: Asia Pacific Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 14: Asia Pacific Market Value (US$ Million) Forecast by Treatment, 2018 to 2033 Table 15: Asia Pacific Market Value (US$ Million) Forecast by End User, 2018 to 2033 Table 16: MEA Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 17: MEA Market Value (US$ Million) Forecast by Treatment, 2018 to 2033 Table 18: MEA Market Value (US$ Million) Forecast by End User, 2018 to 2033
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystList of Charts
Figure 1: Global Market Value (US$ Million) by Treatment, 2023 to 2033 Figure 2: Global Market Value (US$ Million) by End User, 2023 to 2033 Figure 3: Global Market Value (US$ Million) by Region, 2023 to 2033 Figure 4: Global Market Value (US$ Million) Analysis by Region, 2018 to 2033 Figure 5: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033 Figure 6: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033 Figure 7: Global Market Value (US$ Million) Analysis by Treatment, 2018 to 2033 Figure 8: Global Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033 Figure 9: Global Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033 Figure 10: Global Market Value (US$ Million) Analysis by End User, 2018 to 2033 Figure 11: Global Market Value Share (%) and BPS Analysis by End User, 2023 to 2033 Figure 12: Global Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033 Figure 13: Global Market Attractiveness by Treatment, 2023 to 2033 Figure 14: Global Market Attractiveness by End User, 2023 to 2033 Figure 15: Global Market Attractiveness by Region, 2023 to 2033 Figure 16: North America Market Value (US$ Million) by Treatment, 2023 to 2033 Figure 17: North America Market Value (US$ Million) by End User, 2023 to 2033 Figure 18: North America Market Value (US$ Million) by Country, 2023 to 2033 Figure 19: North America Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 20: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 21: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 22: North America Market Value (US$ Million) Analysis by Treatment, 2018 to 2033 Figure 23: North America Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033 Figure 24: North America Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033 Figure 25: North America Market Value (US$ Million) Analysis by End User, 2018 to 2033 Figure 26: North America Market Value Share (%) and BPS Analysis by End User, 2023 to 2033 Figure 27: North America Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033 Figure 28: North America Market Attractiveness by Treatment, 2023 to 2033 Figure 29: North America Market Attractiveness by End User, 2023 to 2033 Figure 30: North America Market Attractiveness by Country, 2023 to 2033 Figure 31: Latin America Market Value (US$ Million) by Treatment, 2023 to 2033 Figure 32: Latin America Market Value (US$ Million) by End User, 2023 to 2033 Figure 33: Latin America Market Value (US$ Million) by Country, 2023 to 2033 Figure 34: Latin America Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 35: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 36: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 37: Latin America Market Value (US$ Million) Analysis by Treatment, 2018 to 2033 Figure 38: Latin America Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033 Figure 39: Latin America Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033 Figure 40: Latin America Market Value (US$ Million) Analysis by End User, 2018 to 2033 Figure 41: Latin America Market Value Share (%) and BPS Analysis by End User, 2023 to 2033 Figure 42: Latin America Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033 Figure 43: Latin America Market Attractiveness by Treatment, 2023 to 2033 Figure 44: Latin America Market Attractiveness by End User, 2023 to 2033 Figure 45: Latin America Market Attractiveness by Country, 2023 to 2033 Figure 46: Europe Market Value (US$ Million) by Treatment, 2023 to 2033 Figure 47: Europe Market Value (US$ Million) by End User, 2023 to 2033 Figure 48: Europe Market Value (US$ Million) by Country, 2023 to 2033 Figure 49: Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 50: Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 51: Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 52: Europe Market Value (US$ Million) Analysis by Treatment, 2018 to 2033 Figure 53: Europe Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033 Figure 54: Europe Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033 Figure 55: Europe Market Value (US$ Million) Analysis by End User, 2018 to 2033 Figure 56: Europe Market Value Share (%) and BPS Analysis by End User, 2023 to 2033 Figure 57: Europe Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033 Figure 58: Europe Market Attractiveness by Treatment, 2023 to 2033 Figure 59: Europe Market Attractiveness by End User, 2023 to 2033 Figure 60: Europe Market Attractiveness by Country, 2023 to 2033 Figure 61: Asia Pacific Market Value (US$ Million) by Treatment, 2023 to 2033 Figure 62: Asia Pacific Market Value (US$ Million) by End User, 2023 to 2033 Figure 63: Asia Pacific Market Value (US$ Million) by Country, 2023 to 2033 Figure 64: Asia Pacific Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 65: Asia Pacific Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 66: Asia Pacific Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 67: Asia Pacific Market Value (US$ Million) Analysis by Treatment, 2018 to 2033 Figure 68: Asia Pacific Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033 Figure 69: Asia Pacific Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033 Figure 70: Asia Pacific Market Value (US$ Million) Analysis by End User, 2018 to 2033 Figure 71: Asia Pacific Market Value Share (%) and BPS Analysis by End User, 2023 to 2033 Figure 72: Asia Pacific Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033 Figure 73: Asia Pacific Market Attractiveness by Treatment, 2023 to 2033 Figure 74: Asia Pacific Market Attractiveness by End User, 2023 to 2033 Figure 75: Asia Pacific Market Attractiveness by Country, 2023 to 2033 Figure 76: MEA Market Value (US$ Million) by Treatment, 2023 to 2033 Figure 77: MEA Market Value (US$ Million) by End User, 2023 to 2033 Figure 78: MEA Market Value (US$ Million) by Country, 2023 to 2033 Figure 79: MEA Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 80: MEA Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 81: MEA Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 82: MEA Market Value (US$ Million) Analysis by Treatment, 2018 to 2033 Figure 83: MEA Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033 Figure 84: MEA Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033 Figure 85: MEA Market Value (US$ Million) Analysis by End User, 2018 to 2033 Figure 86: MEA Market Value Share (%) and BPS Analysis by End User, 2023 to 2033 Figure 87: MEA Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033 Figure 88: MEA Market Attractiveness by Treatment, 2023 to 2033 Figure 89: MEA Market Attractiveness by End User, 2023 to 2033 Figure 90: MEA Market Attractiveness by Country, 2023 to 2033
Need specific information?
Request CustomizationExplore Healthcare Insights
View Reports